Aethlon Medical (AEMD) Stock Price, Quote & News

Company Profile

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Industry: Medical Devices

Sector: Healthcare

Phone: 619 941 0360

Fax: 619 941 0361

Website: www.aethlonmedical.com

Address:

11555 Sorrento Valley Road, Suite 203, San Diego, United States

__ChartMenace Feb. 23 at 12:44 PM

$DHAI $AEMD $PSIG $LPSN 9

0 · Reply

UgoGreg Feb. 22 at 6:47 PM

$AEMD https://youtu.be/nCPt9XhiRxk

0 · Reply

UgoGreg Feb. 22 at 4:35 PM

$AEMD https://youtu.be/VcWJkTGHJVM

0 · Reply

UgoGreg Feb. 22 at 3:18 PM

$AEMD https://youtu.be/JVJuIgdlZA8

0 · Reply

BillionerOfKing Feb. 21 at 8:36 PM

$AEMD Current Stock Price: $1.98

0 · Reply

aafetygod Feb. 20 at 10:40 AM

$IBG $SHFS $AEMD 50~200% runner!

0 · Reply

aafetygod Feb. 20 at 10:03 AM

$AEMD 4.5?

0 · Reply

Magnificent77 Feb. 19 at 6:35 PM

$AEMD yikes they may be dead

0 · Reply

__ChartMenace Feb. 19 at 5:39 PM

$SENS $ETHZ $DHAI $AEMD `

0 · Reply

ZacksSCR Feb. 18 at 3:07 PM

$AEMD: Advancing Oncology Trial; Seeking to Simplify - Potentially Broaden – Device Application https://buff.ly/bo52pwp

0 · Reply

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Feb 19, 2026, 12:25 PM EST - 4 days ago

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Feb 12, 2026, 10:14 PM EST - 10 days ago

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Feb 12, 2026, 4:15 PM EST - 11 days ago

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Feb 4, 2026, 8:01 AM EST - 19 days ago

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

Dec 5, 2025, 9:15 AM EST - 2 months ago

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Dec 2, 2025, 8:01 AM EST - 2 months ago

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

Nov 12, 2025, 6:31 PM EST - 3 months ago

Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript

Nov 12, 2025, 4:15 PM EST - 3 months ago

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Nov 7, 2025, 8:01 AM EST - 3 months ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Oct 7, 2025, 8:01 AM EDT - 4 months ago

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

Sep 4, 2025, 9:15 AM EDT - 6 months ago

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

Sep 3, 2025, 8:01 AM EDT - 6 months ago

Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Aug 13, 2025, 8:01 PM EDT - 6 months ago

Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript

Aug 13, 2025, 4:15 PM EDT - 6 months ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

Aug 5, 2025, 8:01 AM EDT - 7 months ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

Jul 15, 2025, 8:01 AM EDT - 7 months ago

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

Jun 26, 2025, 7:35 PM EDT - 8 months ago

Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript

Jun 26, 2025, 4:15 PM EDT - 8 months ago

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Jun 20, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

Jun 18, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

Jun 9, 2025, 8:01 AM EDT - 9 months ago

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

May 14, 2025, 8:01 AM EDT - 10 months ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Mar 10, 2025, 8:01 AM EDT - 1 year ago

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Feb 13, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Feb 12, 2025, 8:11 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript

Feb 12, 2025, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Feb 5, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Jan 29, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Dec 20, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Nov 14, 2024, 8:00 AM EST - 1 year ago

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Nov 13, 2024, 7:58 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Nov 13, 2024, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Innovative Medical Technology Advances with First Patient Enrollments

Nov 11, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Nov 6, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Sep 19, 2024, 8:01 AM EDT - 1 year ago

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Sep 17, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Present at Virtual Investor Conferences in September

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Innovation Driving Cancer's Solid Tumors Market

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

Sep 13, 2024, 8:35 AM EDT - 1 year ago

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

Aug 27, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Aug 14, 2024, 6:45 PM EDT - 1 year ago

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 12, 2024, 9:01 AM EDT - 1 year ago

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Aug 6, 2024, 9:12 AM EDT - 1 year ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

Jun 27, 2024, 6:37 PM EDT - 1 year ago

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

__ChartMenace Feb. 23 at 12:44 PM

$DHAI $AEMD $PSIG $LPSN 9

0 · Reply

UgoGreg Feb. 22 at 6:47 PM

$AEMD https://youtu.be/nCPt9XhiRxk

0 · Reply

UgoGreg Feb. 22 at 4:35 PM

$AEMD https://youtu.be/VcWJkTGHJVM

0 · Reply

UgoGreg Feb. 22 at 3:18 PM

$AEMD https://youtu.be/JVJuIgdlZA8

0 · Reply

BillionerOfKing Feb. 21 at 8:36 PM

$AEMD Current Stock Price: $1.98

0 · Reply

aafetygod Feb. 20 at 10:40 AM

$IBG $SHFS $AEMD 50~200% runner!

0 · Reply

aafetygod Feb. 20 at 10:03 AM

$AEMD 4.5?

0 · Reply

Magnificent77 Feb. 19 at 6:35 PM

$AEMD yikes they may be dead

0 · Reply

__ChartMenace Feb. 19 at 5:39 PM

$SENS $ETHZ $DHAI $AEMD `

0 · Reply

ZacksSCR Feb. 18 at 3:07 PM

$AEMD: Advancing Oncology Trial; Seeking to Simplify - Potentially Broaden – Device Application https://buff.ly/bo52pwp

0 · Reply

PikaPlays Feb. 18 at 12:44 PM

$SENS $ETHZ $DHAI $AEMD 5

0 · Reply

TriggerScout Feb. 18 at 9:28 AM

$AEMD Medical device play where regulatory milestones unlock value.

0 · Reply

BreakoutPika Feb. 17 at 6:25 PM

$ETHZ $DHAI $AEMD $PSIG >

0 · Reply

OfficialStocktwitsUser Feb. 17 at 11:25 AM

$AEMD RSI: 7.32, MACD: -0.2426 Vol: 0.38, MA20: 2.50, MA50: 2.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

FadeLars Feb. 17 at 8:55 AM

$AEMD Pre-revenue medtech; early-stage

0 · Reply

PlatinumLambos Feb. 15 at 5:58 AM

$AEMD Pre-revenue medtech; early-stage, binary regulatory outcomes.

0 · Reply

BillionerOfKing Feb. 14 at 12:07 AM

$AEMD Current Stock Price: $2.03

0 · Reply

pitkineagle Feb. 12 at 10:35 PM

$AEMD Their main patents for extracorporeal removal of microvesicular particles and virus capture expire later this decade. I don’t think investing in their stock makes much sense at all.

0 · Reply

StocktwitsEarnings Feb. 12 at 10:17 PM

$AEMD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$2.45 up 75.62% YoY • Aethlon Medical Inc explicitly states existing cash as of December 31, 2025, is not expected to fund operations for at least twelve months, anticipating increasing negative cash flows and net losses for the foreseeable future.

0 · Reply

TriggerRaider Feb. 9 at 12:51 PM

$AEMD is a medical device company (Aethlon Medical) developing a blood filtration device; novel medical devices face long regulatory and clinical validation pathways.

0 · Reply

BioTechHealthX Feb. 6 at 11:30 AM

$AEMD Aethlon Medical (NASDAQ:AEMD) is developing a breakthrough FDA-designated device that removes harmful viruses and cancer-related exosomes directly from the blood. As investors obsess over earnings, the real story may be hiding in plain sight. https://biotechhealthx.com/biotech-news/heres-why-you-should-invest-in-aethlon-medical-aemd/

0 · Reply

BioTechHealthX Feb. 6 at 10:53 AM

$DNA $AEMD $ABCL $SXTC $CNTN Biotech stocks often surge on news tied to clinical progress and regulatory updates. Learn why breakthroughs in drug discovery, genetics, and AI are translating into rapid price action across the sector today. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/

0 · Reply

Market Cap	2.64M
Revenue (ttm)	0.00
Net Income (ttm)	-13.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	12,703
Avg Vol	56,474
Day's Range	N/A - N/A
Shares Out	1.32M
Stochastic %K	33%
Beta	1.60
Analysts	Hold
Price Target	$4.75